Trial Profile
A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Trebananib (Primary) ; Bevacizumab; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Amgen
- 28 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 27 Jan 2014 Planned End Date changed from 1 Oct 2013 to 1 Dec 2014, according to ClinicalTrials.gov record.
- 09 Oct 2012 Planned End Date changed from 1 Sep 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov record.